9.59  -0.46 (-4.58%)		04-24 14:33
Open: 10.03 High: 10.06 Volume: 253,266		Pre. Close: 10.05 Low: 9.59 Market Cap: 794(M)

Short term
Mid term
Targets	6-month :	13.18	1-year :	14.59
Resists	First :	11.28	Second :	12.5
Pivot price	10.04
Supports	First :	9.31	Second :	7.75
MAs	MA(5) :	9.78	MA(20) :	10.53
	MA(100) :	11.6	MA(250) :	13.37
MACD	MACD :	-0.4	Signal :	-0.4
%K %D	K(14,3) :	13.1	D(3) :	12.3
RSI	RSI(14): 41.7
52-week	High :	19.71	Low :	7.94

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ FNA ] has closed above bottom band by 20.6%. Bollinger Bands are 56.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	10.19 - 10.24	10.24 - 10.28
Low:	9.63 - 9.69	9.69 - 9.74
Close:	9.96 - 10.05	10.05 - 10.13

Paragon 28, Inc. designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; and APEX 3D total ankle replacement systems; total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides bunion or hallux valgus correction systems, including nail systems phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.

Wed, 17 Apr 2024
Many Still Looking Away From Paragon 28, Inc. (NYSE:FNA) - Simply Wall St

Sat, 13 Apr 2024
Short Interest in Paragon 28, Inc. (NYSE:FNA) Rises By 30.6% - MarketBeat

Thu, 04 Apr 2024
Lamb Weston Reports Weak Earnings, Joins Paragon 28, Resources Connection And Other Big Stocks Moving Low - Benzinga

Thu, 04 Apr 2024
Paragon 28 Announces CFO Transition, Provides Preliminary Unaudited Net Revenue for First Quarter 2024, and ... - OrthoSpineNews

Thu, 04 Apr 2024
Lamb Weston Reports Weak Earnings, Joins Paragon 28, Resources Connection And Other Big Stocks Moving Lower ... - Markets Insider

Mon, 01 Apr 2024
Paragon 28 (FNA) Expands Syndesmotic Repair Line With New Launch - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NYSE
Sector: Healthcare
Industry: Medical - Devices
Shares Out	83 (M)
Shares Float	39 (M)
Held by Insiders	39.8 (%)
Held by Institutions	49.6 (%)
Shares Short	2,430 (K)
Shares Short P.Month	1,660 (K)

EPS	-0.58
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.15
Profit Margin	-22.2 %
Operating Margin	-18.6 %
Return on Assets (ttm)	-7.9 %
Return on Equity (ttm)	-30.1 %
Qtrly Rev. Growth	17.6 %
Gross Profit (p.s.)	0
Sales Per Share	2.6
EBITDA (p.s.)	-0.27
Qtrly Earnings Growth	0 %
Operating Cash Flow	-64 (M)
Levered Free Cash Flow	-80 (M)

PE Ratio	-16.66
PEG Ratio	-0.8
Price to Book value	4.49
Price to Sales	3.7
Price to Cash Flow	-12.54

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.